A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages IIIB/C/IV Melanoma.

Trial Profile

A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages IIIB/C/IV Melanoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Jul 2017.
    • 17 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top